Homogeneous Immunoassays—Therapeutic Drug Monitoring
QMS®—Latex Enhanced Immunoturbidimetric Assays
Lidocaine Assay System
The LIDOCAINE Assay System is intended for the quantitative determination of total Lidocaine in serum for therapeutic drug monitoring.
Lidocaine is an antiarrhythmic agent administered intravenously by either injection or continuous infusion. Concentration monitoring is warranted by lidocaine's extensive interpatient variability in disposition and by its narrow therapeutic index1. Lidocaine is 60 to 80% bound to plasma proteins. The therapeutic range for total concentration is stated as 1.5 to 6 µg/mL2. Suppression of ventricular arrhythmias at concentrations above 2 µg/mL is likely, but prevention of primary ventricular fibrillation may require higher concentrations. At concentrations exceeding 6 µg/mL the frequency of CNS toxicity increases. A significant number of patients may require concentrations of 6 to 9 µg/mL for arrhythmia control3. The benefits and risks of Lidocaine concentrations above 6 µg/mL must be determined carefully. Lidocaine metabolites may contribute to toxicity in patients receiving prolonged infusions or in patients with renal insufficiency.
